Compare KALA & POAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KALA | POAS |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5M | 2.3M |
| IPO Year | 2017 | 2024 |
| Metric | KALA | POAS |
|---|---|---|
| Price | $3.04 | $3.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 164.5K | ★ 2.9M |
| Earning Date | 12-01-2026 | 08-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 67.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $0.13 |
| 52 Week High | $191.00 | $7.40 |
| Indicator | KALA | POAS |
|---|---|---|
| Relative Strength Index (RSI) | 77.25 | 66.83 |
| Support Level | $2.07 | $0.27 |
| Resistance Level | $3.71 | $5.60 |
| Average True Range (ATR) | 0.14 | 0.80 |
| MACD | 0.38 | 0.17 |
| Stochastic Oscillator | 73.26 | 51.52 |
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Phaos Technology Holdings Cayman Ltd is an investment holding company incorporated in the Cayman Islands. Through its subsidiaries, the Company engages in the research, development, manufacturing, and commercialization of optical technologies and products. Leveraging its patented microsphere technology, Phaos enhances the magnification of traditional optical microscopes, enabling visualization beyond the 200nm optical limit at a commercially viable working distance. The Company offers high tech microscopy equipment and parts, along with AI-powered software solutions that complement its hardware to deliver fully integrated microscopy systems. Its technologies serve diverse sectors, including manufacturing, biomedical, and research.